Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Apr, 2015 | Pages:
137 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Osteosarcoma - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Osteosarcoma - Pipeline Review, H1 2015', provides an overview of the Osteosarcoma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Osteosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteosarcoma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Osteosarcoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Osteosarcoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Osteosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Osteosarcoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Osteosarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Osteosarcoma Overview 9 Therapeutics Development 10 Pipeline Products for Osteosarcoma - Overview 10 Pipeline Products for Osteosarcoma - Comparative Analysis 11 Osteosarcoma - Therapeutics under Development by Companies 12 Osteosarcoma - Therapeutics under Investigation by Universities/Institutes 13 Osteosarcoma - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Osteosarcoma - Products under Development by Companies 16 Osteosarcoma - Products under Investigation by Universities/Institutes 17 Osteosarcoma - Companies Involved in Therapeutics Development 18 Advaxis, Inc. 18 Amgen Inc. 19 Bayer AG 20 Bellicum Pharmaceuticals, Inc. 21 Eleison Pharmaceuticals, Inc. 22 Exelixis, Inc. 23 Isofol Medical AB 24 Merck & Co., Inc. 25 Merrimack Pharmaceuticals, Inc. 26 Neusentis 27 Novartis AG 28 Sutro Biopharma, Inc. 29 Osteosarcoma - Therapeutics Assessment 30 Assessment by Monotherapy Products 30 Assessment by Combination Products 31 Assessment by Target 32 Assessment by Mechanism of Action 35 Assessment by Route of Administration 37 Assessment by Molecule Type 39 Drug Profiles 41 ADXS-HER2 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 alendronate sodium + HPMA + TNP-470 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 AM-7209 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 BL-1249 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 cabozantinib s-malate - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Cell Therapy for GD2 Expressing Solid Tumors - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Cell Therapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 celyvir - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 cisplatin - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 everolimus - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 irinotecan sucrosofate liposomal - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 ISOMC-091 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 LLL-12 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 MBC-11 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Monoclonal Antibody to Target GD2 for Osteosarcoma - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 pazopanib hydrochloride - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 pembrolizumab - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 radium Ra 223 dichloride - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Vaccine for Osteosarcoma - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Osteosarcoma - Recent Pipeline Updates 88 Osteosarcoma - Dormant Projects 130 Osteosarcoma - Discontinued Products 131 Osteosarcoma - Product Development Milestones 132 Featured News & Press Releases 132 Nov 04, 2014: Advaxis to Present Data of ADXS-cHER2 at the Society for Immunotherapy of Cancer 29th Annual Meeting 132 Oct 30, 2014: Advaxis's ADXS-cHER2 Immunotherapy Demonstrates T-Cell Immune Response in Data Analysis From Canine Osteosarcoma Study 132 May 27, 2014: Advaxis's HER2 Immunotherapy Candidate Receives Orphan Drug Designation for Treatment of Osteosarcoma 133 Mar 17, 2014: First Cancer Trial Launched Using CAR T Cells Engineered with a Safety Switch 133 Oct 08, 2013: ILC Granted Orphan Drug Designation in Europe for the Treatment of Osteosarcoma 135 Appendix 136 Methodology 136 Coverage 136 Secondary Research 136 Primary Research 136 Expert Panel Validation 136 Contact Us 136 Disclaimer 137
List of Tables
Number of Products under Development for Osteosarcoma, H1 2015 10 Number of Products under Development for Osteosarcoma - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 12 Number of Products under Investigation by Universities/Institutes, H1 2015 13 Comparative Analysis by Clinical Stage Development, H1 2015 14 Comparative Analysis by Early Stage Development, H1 2015 15 Products under Development by Companies, H1 2015 16 Products under Investigation by Universities/Institutes, H1 2015 17 Osteosarcoma - Pipeline by Advaxis, Inc., H1 2015 18 Osteosarcoma - Pipeline by Amgen Inc., H1 2015 19 Osteosarcoma - Pipeline by Bayer AG, H1 2015 20 Osteosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 21 Osteosarcoma - Pipeline by Eleison Pharmaceuticals, Inc., H1 2015 22 Osteosarcoma - Pipeline by Exelixis, Inc., H1 2015 23 Osteosarcoma - Pipeline by Isofol Medical AB, H1 2015 24 Osteosarcoma - Pipeline by Merck & Co., Inc., H1 2015 25 Osteosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 26 Osteosarcoma - Pipeline by Neusentis, H1 2015 27 Osteosarcoma - Pipeline by Novartis AG, H1 2015 28 Osteosarcoma - Pipeline by Sutro Biopharma, Inc., H1 2015 29 Assessment by Monotherapy Products, H1 2015 30 Assessment by Combination Products, H1 2015 31 Number of Products by Stage and Target, H1 2015 33 Number of Products by Stage and Mechanism of Action, H1 2015 36 Number of Products by Stage and Route of Administration, H1 2015 38 Number of Products by Stage and Molecule Type, H1 2015 40 Osteosarcoma Therapeutics - Recent Pipeline Updates, H1 2015 88 Osteosarcoma - Dormant Projects, H1 2015 130 Osteosarcoma - Discontinued Products, H1 2015 131
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
